IRIS
BASSET, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 700
EU - Europa 504
AS - Asia 246
AF - Africa 4
SA - Sud America 2
OC - Oceania 1
Totale 1.457
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 697
IE - Irlanda 312
CN - Cina 234
FI - Finlandia 71
DE - Germania 48
IT - Italia 42
SE - Svezia 15
AT - Austria 8
IN - India 7
CA - Canada 3
CL - Cile 2
FR - Francia 2
GR - Grecia 2
IR - Iran 2
MU - Mauritius 2
AU - Australia 1
BE - Belgio 1
EG - Egitto 1
ES - Italia 1
GB - Regno Unito 1
JP - Giappone 1
LU - Lussemburgo 1
MY - Malesia 1
SA - Arabia Saudita 1
SL - Sierra Leone 1
Totale 1.457
Salva come PNG Salva come JPEG
Città #
Dublin 310
Chandler 208
Ashburn 79
Helsinki 59
Nanjing 54
Beijing 50
Princeton 35
Lawrence 34
Medford 31
Shanghai 27
Wilmington 26
Nanchang 20
Jacksonville 19
Pavia 19
Changsha 15
Shenyang 15
Hebei 14
Piscataway 13
Tianjin 11
Jiaxing 10
New York 10
Norwalk 7
Pune 7
Tamm 6
Woodbridge 6
Fairfield 5
Hangzhou 5
Los Angeles 5
Redwood City 5
Seattle 5
Cagliari 4
Falkenstein 4
Milan 4
Vienna 4
Washington 4
Catania 3
Athens 2
Fuzhou 2
Houston 2
Ningbo 2
Palermo 2
Taizhou 2
Vinovo 2
Zhengzhou 2
Andover 1
Ann Arbor 1
Baltimore 1
Brussels 1
Cairo 1
Clearwater 1
Des Moines 1
Freetown 1
Haikou 1
Hanover 1
Jinan 1
Kish 1
Laurel 1
London 1
Luxembourg 1
Markham 1
Nagold 1
Nova Milanese 1
Orange 1
Riyadh 1
Saint-Alexis-de-Matapedia 1
San Diego 1
San Francisco 1
Sassari 1
Selangor 1
Shiraz 1
Sydney 1
Toronto 1
Totale 1.177
Salva come PNG Salva come JPEG
Nome #
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 63
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 63
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 56
A patient with AL amyloidosis with negative free light chain results 54
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 50
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 49
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 48
Prognostication of survival and progression to dialysis in AA amyloidosis 45
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 45
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 44
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 43
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 42
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 41
A biomarker-based approach in management of AL amyloidosis: from risk assessment to tailored-treatment strategy 41
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 40
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 38
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 38
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 37
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 36
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 36
The lung in amyloidosis 32
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 32
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 32
null 30
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 30
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 30
null 29
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 29
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 28
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 27
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 26
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 25
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 25
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 24
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 23
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 22
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 22
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 22
A case of monoclonal gammopathy of renal significance 21
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 20
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 20
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 20
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 19
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 14
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 14
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 8
Renal amyloidoses 6
null 6
Totale 1.545
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.101
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 0 0 0 0 0 0 0 0 2
2019/2020215 58 95 0 0 0 0 2 0 1 28 14 17
2020/202168 8 0 2 3 1 5 3 17 25 2 0 2
2021/2022154 2 0 1 0 5 3 0 12 9 14 17 91
2022/2023698 59 62 11 31 46 56 13 35 351 3 21 10
2023/2024325 44 78 17 26 30 68 12 20 2 15 13 0
Totale 1.545